GLEN ALLEN, Va., Oct. 7 /PRNewswire-FirstCall/ -- Star Scientific, Inc. (Nasdaq: CIGX) has issued the following comment by Paul L. Perito, Rock Creek Pharmaceuticals' Chairman and CEO:
"We are gratified that the Roskamp Institute, a highly credentialed scientific foundation, has made a significant medical discovery that we believe holds the potential for creating a therapy that could play a role in alleviating the scourge of Alzheimer's Disease. We are equally grateful that our talented scientific and medical team, inspired by the creativity of our parent company's founder, Jonnie R. Williams, has developed a compound, RCP-006, which the Roskamp Institute believes merits human clinical trials. We trust that these trials will determine the effectiveness of RCP-006 in treating this debilitating disease.Star Scientific has acted expeditiously to protect our company's intellectual property rights and, in that regard, has filed patent applications with the PTO relating to the formulation of the RCP-006 compound and its multiple uses.
On April 7, 2010, Star Scientific announced that it had finalized a Research and Royalty Agreement with the Roskamp Institute affiliate, SRQ BIO, LLC. To date, extensive pre-clinical research has been conducted under that agreement."
Certain statements in this press release other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "continues," "likely," "may," "opportunity," "potential," "projects," "will," "expects," "plans," "intends" and similar expressions to identify forward-looking statements, whether in the negative or the affirmative. These statements reflect our current beliefs and are based on information currently available to us. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance or achievements to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties, factors and contingencies include, without limitation, the challenges inherent in new product development initiatives through Star Tobacco and Rock Creek, the uncertainties inherent in the progress of scientific research, our ability to raise additional capital in the future that is necessary to maintain our business, potential disputes concerning our intellectual property, risks associated with litigation regarding such intellectual property, uncertainties associated with the development, testing and regulatory approvals of our low-TSNA tobacco, related tobacco products and pharmaceutical and nutraceutical products , market acceptance of our new smokeless tobacco products and nutraceutical and pharmaceutical products, competition from companies with greater resources than us, our dependence on key employees and on our prior strategic relationships with Brown & Williamson Tobacco Corporation in light of its combination with R.J. Reynolds Tobacco Company, Inc.
Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that the expectations will be attained or that any deviation will not be material. See additional discussion under "Risk Factors" in the Company's Annual Report on Form 10-K as filed with the SEC on March 16, 2010, and other factors detailed from time to time in the Company's other filings with the SEC, available at www.sec.gov. All information in this release is current as of this date, and the Company undertakes no obligation to update or advise upon any such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
About Star ScientificStar Scientific is a technology-oriented company with a mission to reduce the harm associated with tobacco at every level. It is engaged in the development of dissolvable smokeless tobacco products that deliver fewer carcinogenic toxins, principally through the utilization of the innovative StarCured® tobacco curing technology. Its subsidiary, Rock Creek Pharmaceuticals, Inc., is involved in the development of nutraceuticals as well as products to address neurological and mood disorders. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, D.C. Star Scientific has a Corporate and Sales Office in Glen Allen, VA, an Executive, Scientific & Regulatory Affairs office in Bethesda, MD, and a manufacturing facility in Chase City, VA.
|SOURCE Star Scientific, Inc.|
Copyright©2010 PR Newswire.
All rights reserved